HCV / Hepatitis

According to the Belgian researchers, Sofosbuvir in combination with simeprevir with or without ribarivirn was found to be well-tolerated and efficacious.

In a review article published in Rheumatic Disease Clinics of North America, researchers discuss the main rheumatologic diseases associated with chronic HCV infection, and how DAAs have affected these extrahepatic manifestations.

Monique Foster, MD, MPH, EIS officer, Division of Viral Hepatitis, Centers for Disease Control and Prevention (CDC), discusses the CDC’s HCV universal birth cohort testing program.

A research group from Hokkaido University in Japan found that standard treatment for those with genotype 1 HCV should likely be switched from interferon (INF)-based therapies to INF-free direct-acting antiviral (DAA) therapies.

A report warns that liver failure might be associated with nine new direct-acting antivirals (DAA).

A group of researchers recently published a study in JAMA, examining conflicts of interest (COIs) among committee members who set hepatitis C (HCV) and cholesterol management guidelines. They found that there, in fact, were COIs among committee members setting HCV management guidelines.

The European Medicines Agency has fully validated Gilead’s SOf/VEL/VOX regimen to treat hepatitis C (HCV).

Monique Foster, MD, MPH, EIS officer, Division of Viral Hepatitis, Centers for Disease Control and Prevention, explains that hepatitis C infection awareness has been on the rise in the United States.

Felix Kleefeld, of Berlin, Germany, and colleagues examined how eradicating HCV affected the cognition of patients in a study published in Neurology in December 2016.

Researchers conducted a post hoc analysis to learn whether or not the length of time it took to attain initial viral suppression is related to sustained virologic response (SVR) rates for patients receiving the so-call 3D treatment, with or without ribavirin.

Insurance companies are denying members coverage to expensive drugs, like Harvoni, and those infected with HCV are filing lawsuits.

Monique Foster, MD, MPH, EIS officer, Division of Viral Hepatitis, Centers for Disease Control and Prevention, discusses the importance of new medications to treat hepatitis C.

A new project aims to develop and assess new hepatitis C vaccination strategies in an effort to improve treatment.

Researchers offer more insight on the role of IFN-I and find a potential therapeutic target that may be able to protect against chronic viral infections.

New research from the Medical University of Vienna has made a connect between blood infections and an increased risk of arteriosclerosis.

In a phase 3 clinical trial, Japanese patients with chronic hepatitis C (HCV) infection without liver cirrhosis were able to achieve high sustained viral response rates after taking an investigational HCV drug from AbbVie.

Monique Foster, MD, MPH, EIS officer, Division of Viral Hepatitis, Centers for Disease Control and Prevention, explains why it’s important for individuals to know that they are infected with hepatitis C, although they may be asymptomatic.

A new biotechnology company, Vir Biotechnology, is gunning for bear in the fight against infectious diseases and boasting a roster of heavy hitters in the industry.

Despite the fact that an increasingly large portion of the hepatitis C (HCV)-infected population successfully achieves a cure for the infection, called sustained viral response (SVR), this population still deals with increased mortality rates.

Harvoni has been added to Express Script’s formulary and will be available from the company’s Hepatitis Cure Value Program.

The European Medicines Agency (EMA) released guidelines recommending screening for hepatitis B in patients who are infected with hepatitis C prior to starting treatment with direct-acting antivirals.

Researchers from Purdue University have discovered a connection between hepatitis B (HBV) infection and liver cancer.

Why do more HCV-infected immigrants, rather than non-immigrants, end up hospitalized for liver problems? Inadequate screening and longer infection duration are likely reasons.

In a review article, researchers share current understanding of the pathogenesis of type IV T cell-dependent immune-mediated ADRs and review the evidence for diagnostics for T cell-mediated ADRs.

Buyers clubs are still going strong in the United States and around the world as the offer a low-cost alternative for individuals with HIV and hepatitis c virus (HCV) who often find themselves struggling to pay for the expensive medications they need to treat their illness.

Researchers have not been able to develop a vaccine for hepatitis C, which causes 700,000 deaths around the world annually, and now, a new study shows why developing a vaccine for the virus has been so difficult.

A team of researchers at the University of California has found that veterans infected with both hepatitis C and human immunodeficiency virus sought treatment more often than those infected with just one of the viruses.

The FDA has released a warning on the risk of reactivation of hepatitis B virus in some patients receiving direct-action antivirals to treat hepatitis C infection.